Her2+ Non Small Cell Lung Cancer Market: Epidemiology, Therapies, Companies, DelveInsight | Spectrum Pharmaceuticals, AstraZeneca, Daiichi Sankyo, Jiangsu HengRui Medicine, Dizal Pharmaceuticals, Takeda Pharmaceuticals

Her2+ Non Small Cell Lung Cancer therapies, such as Pyrotinib, DZD9008, Mobocertinib (TAK-788), and others, are expected to boost the Her2+ Non Small Cell Lung Cancer Market in the upcoming years.

DelveInsight has launched a new report on "Her2+ Non Small Cell Lung Cancer - Market Insights, Epidemiology, and Market Forecast-2034" that delivers an in-depth understanding of the Her2+ Non Small Cell Lung Cancer, historical and forecasted epidemiology as well as the Her2+ Non Small Cell Lung Cancer market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Discover about the Her2+ Non Small Cell Lung Cancer market report @ https://www.delveinsight.com/report-store/her2-non-small-cell-lung-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Some of the key facts of the Her2+ Non Small Cell Lung Cancer Market Report:

The HER2+ NSCLC market (covering mutations, overexpression, and amplification) in the 7MM was valued at approximately USD 850 million in 2023 and is projected to grow to around USD 3,110 million by 2034, with a CAGR of 13.2%. NSCLC accounts for about 80-85% of all lung cancer cases, with HER2+ gene mutations present in roughly 1-4% of these patients. Additionally, HER2+ amplification and overexpression occur in about 2-5% and 2-30% of NSCLC cases, respectively, in the US.
In May 2025, For adults with advanced non-squamous NSCLC overexpressing the c-Met protein, who have received prior treatments. Emrelis is the first FDA-approved therapy targeting c-Met overexpression in NSCLC, offering a new targeted treatment option.
In December 2024, For adults with advanced, unresectable, or metastatic NSCLC harboring a neuregulin 1 (NRG1) gene fusion, with disease progression on or after prior systemic therapy. Zenocutuzumab-zbco is the first FDA-approved therapy targeting NRG1 gene fusions in NSCLC, offering a new treatment avenue for this rare molecular subset.
In April 2024, For adults with unresectable or metastatic HER2-positive (IHC 3+) solid tumors, including NSCLC, who have received prior systemic treatment and have no satisfactory alternative treatment options. This approval marks Enhertu as the first tumor-agnostic HER2-directed therapy, expanding treatment options for patients with various HER2-positive cancers.
Current treatment options for HER2-mutant NSCLC include chemotherapy, targeted therapies, immunotherapy, laser therapy, photodynamic therapy, radiation, surgery, and other approaches. ENHERTU (trastuzumab deruxtecan) is the only FDA-approved drug for adults with unresectable or metastatic NSCLC harboring activating HER2+ (ERBB2) mutations who have received prior systemic treatment. This drug received accelerated approval in August 2022 but is currently approved only for later-line therapy, leaving unmet needs in the first-line setting.
Recently, new, more selective oral HER2+ tyrosine kinase inhibitors (TKIs) have been developed to enhance outcomes for NSCLC patients with HER2+ mutations and potentially challenge ENHERTU's market position.
The HER2+ NSCLC pipeline includes several promising candidates such as Pyrotinib (Jiangsu HengRui Medicine), Zongertinib (Boehringer Ingelheim), BAY 2927088 (Bayer), FWD1509 (Forward Pharmaceuticals), ORIC-114 (ORIC Pharmaceuticals), IAM1363 (Iambic Therapeutics), Firmonertinib (ArriVent BioPharma), XMT-2056 (Mersana Therapeutics/GSK), among others in various clinical trial stages. The introduction of these therapies is expected to significantly influence the HER2+ NSCLC market between 2024 and 2034.
In the US, the total diagnosed NSCLC cases by stage in 2023 were approximately 59,400 for stage I, 16,900 for stage II, 26,700 for stage IIIA, 11,200 for stage IIIB, and 88,300 for stage IV.
In the same year, the total incident cases of advanced HER2+ NSCLC in the US were about 6,000 for HER2+ gene mutation, 32,400 for HER2+ gene overexpression, and 8,100 for HER2+ gene amplification.
Key Her2+ Non Small Cell Lung Cancer companies such as Spectrum Pharmaceuticals, AstraZeneca, Daiichi Sankyo, Jiangsu HengRui Medicine, Dizal Pharmaceuticals, Takeda Pharmaceuticals, and others are evaluating new drugs for Her2+ Non Small Cell Lung Cancer to improve the treatment landscape.
Promising Her2+ Non Small Cell Lung Cancer therapies include Pyrotinib, DZD9008, Mobocertinib (TAK-788), and others.

Her2+ Non Small Cell Lung Cancer Overview

HER2+, also known as ERBB2, is a receptor tyrosine kinase encoded by the ERBB2 proto-oncogene located on the long arm of chromosome 17 (17q21). It belongs to the EGFR/ErbB family, which includes HER1/EGFR, HER2+, HER3, and HER4. Unlike other members of this family, HER2+ has no known ligand. Its activation occurs through homodimerization or heterodimerization with another ligand-bound HER family receptor, leading to cross-phosphorylation and activation of its tyrosine kinase domain.

In NSCLC, three primary mechanisms of HER2+ dysregulation have been identified: gene mutation, gene amplification, and protein overexpression. These alterations arise from different processes and result in distinct biological and clinical effects. HER2+ changes influence both the tumor cell biology and patient outcomes, playing a crucial role in determining therapeutic approaches for NSCLC patients. Common symptoms of HER2+ NSCLC include persistent coughing, chest pain, shortness of breath, wheezing, loss of appetite, weight loss, and unusual fatigue.

Her2+ Non Small Cell Lung Cancer Market Outlook

HER2+ alterations are key oncogenic drivers in NSCLC. In recent years, significant progress has been made in characterizing HER2+-driven disease and evaluating the effectiveness of various agents targeting HER2+. Currently, platinum-based chemotherapy, with or without immunotherapy, remains the preferred first-line treatment for patients with advanced or metastatic HER2+ NSCLC. Historically, the standard treatments-including chemotherapy, immunotherapy, checkpoint inhibitors, and targeted cell therapies-have only achieved a median progression-free survival (PFS) of about 4 months, highlighting the urgent need for better therapeutic options.

ENHERTU (trastuzumab deruxtecan) was approved by the FDA in August 2022 for HER2+-mutant NSCLC patients who had received prior systemic therapy, marking a major shift in treatment for this population. ENHERTU also received approval from Japan's Ministry of Health, Labour and Welfare (MHLW) in August 2023, followed by regulatory approval in Europe the next month.

The treatment landscape for HER2+ NSCLC is rapidly evolving as ongoing research reveals more about the genetic drivers of these tumors. New drugs such as Pyrotinib (Jiangsu HengRui Medicine), Zongertinib (Boehringer Ingelheim), and BAY2927088 (Bayer) are attracting attention for HER2+-mutant NSCLC. The development of these novel HER2-targeted tyrosine kinase inhibitors (TKIs) reflects a shift toward more selective and effective therapies. Additionally, other candidates like FWD1509 (Forward Pharmaceuticals), IAM1363 (Iambic Therapeutics), ORIC-114 (ORIC Pharmaceuticals), Firmonertinib (ArriVent BioPharma), and more are in various stages of clinical trials, driving innovation and competition in the HER2+ NSCLC field. Combination treatments are also under investigation to boost the effectiveness of anti-HER2 therapies.

Discover how the Her2+ Non Small Cell Lung Cancer market is rising in the coming years @ https://www.delveinsight.com/sample-request/her2-non-small-cell-lung-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Her2+ Non Small Cell Lung Cancer Marketed Drugs
ENHERTU (trastuzumab deruxtecan): Daiichi Sankyo and AstraZeneca
Her2+ Non Small Lung Cancer Emerging Drugs
Zongertinib (BI-1810631): Boehringer Ingelheim
BAY 2927088: Bayer

Scope of the Her2+ Non Small Cell Lung Cancer Market Report
Study Period: 2020-2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Her2+ Non Small Cell Lung Cancer Companies: Spectrum Pharmaceuticals, AstraZeneca, Daiichi Sankyo, Jiangsu HengRui Medicine, Dizal Pharmaceuticals, Takeda Pharmaceuticals, and others.
Key Her2+ non small cell lung cancer therapies: Pyrotinib, DZD9008, Mobocertinib (TAK-788), and others.
Her2+ Non Small Cell Lung Cancer Therapeutic Assessment: Her2+ Non Small Cell Lung Cancer current marketed and Her2+ Non Small Cell Lung Cancer emerging therapies
Her2+ Non Small Cell Lung Cancer Market Dynamics: Her2+ Non Small Cell Lung Cancer market drivers and Her2+ Non Small Cell Lung Cancer market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Her2+ Non Small Cell Lung Cancer Unmet Needs, KOL's views, Analyst's views, Her2+ Non Small Cell Lung Cancer Market Access and Reimbursement

To know what's more in our Her2+ Non Small Cell Lung Cancer report, visit https://www.delveinsight.com/report-store/her2-non-small-cell-lung-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Key benefits of the Her2+ Non Small Cell Lung Cancer Market Report:
Her2+ Non Small Cell Lung Cancer market report covers a descriptive overview and comprehensive insight of the Her2+ Non Small Cell Lung Cancer Epidemiology and Her2+ Non Small Cell Lung Cancer market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan).
The Her2+ Non Small Cell Lung Cancer market report provides insights into the current and emerging therapies.
The Her2+ Non Small Cell Lung Cancer market report provides a global historical and forecasted market covering drug outreach in 7MM.
The Her2+ Non Small Cell Lung Cancer market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Her2+ Non Small Cell Lung Cancer market.

Got queries? Click here to know more about the Her2+ Non Small Cell Lung Cancer market Landscape https://www.delveinsight.com/sample-request/her2-non-small-cell-lung-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Contents

1. Report Introduction
2. Executive Summary
3. SWOT analysis
4. Her2+ Non Small Cell Lung Cancer Patient Share (%) Overview at a Glance
5. Her2+ Non Small Cell Lung Cancer Market Overview at a Glance
6. Her2+ Non Small Cell Lung Cancer Disease Background and Overview
7. Her2+ Non Small Cell Lung Cancer Epidemiology and Patient Population
8. Country-Specific Patient Population of Her2+ Non Small Cell Lung Cancer
9. Her2+ Non Small Cell Lung Cancer Current Treatment and Medical Practices
10. Unmet Needs
11. Her2+ Non Small Cell Lung Cancer Emerging Therapies
12. Her2+ Non Small Cell Lung Cancer Market Outlook
13. Country-Wise Her2+ Non Small Cell Lung Cancer Market Analysis (2020-2034)
14. Market Access and Reimbursement of Therapies
15. Market drivers
16. Market barriers
17. Appendix
18. Her2+ Non Small Cell Lung Cancer Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Click here to read more about Her2+ Non Small Cell Lung Cancer Market Outlook 2034 https://www.delveinsight.com/report-store/her2-non-small-cell-lung-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Related Reports:

Her2+ Non Small Cell Lung Cancer Pipeline Insights, DelveInsight

"Her2+ Non Small Cell Lung Cancer Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Her2+ Non Small Cell Lung Cancer market. A detailed picture of the Her2+ Non Small Cell Lung Cancer pipeline landscape is provided, which includes the disease overview and Her2+ Non Small Cell Lung Cancer treatment guidelines.

Contact Info:

Kritika Rehani, Assistant Manager, Marketing & Branding
krehani@delveinsight.com
info@delveinsight.com
www.delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.